LDN193189 (GMP)

LDN193189 (DM-3189) (GMP) is LDN193189 (HY-12071) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LDN193189 is selective BMP type I receptor inhibitor[1][2].

Product Specifications

CAS Number

[1062368-24-4]

Product Name Alternative

DM-3189 (GMP)

UNSPSC

12352005

Target

TGF-β Receptor

Type

GMP Small Molecules

Related Pathways

TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ldn193189-gmp.html

Solubility

10 mM in DMSO

Smiles

C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16

Molecular Formula

C25H22N6

Molecular Weight

406.49

References & Citations

[1]Kim TW, et al. Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. Cell Stem Cell. 2021 Feb 4;28 (2) :343-355.e5.|[2]Pagliuca FW, et al. Generation of functional human pancreatic β cells in vitro. Cell. 2014 Oct 9;159 (2) :428-39.